A technology invented by Munich Technology university has been in development by this Munich area company.The new class of molecules called Anticalin are recombinantly engineered lipocalins and represent a next generation therapeutic human protein class proprietary to the company.

Their lead molecule is targeting VEGF for the treatment of solid tumors, has been tested in a phase 1 open-label, dose escalating trial and is found to be safe and well tolerated.  Out of its database of several hundred companies, Aagami has identified over 3 dozen companies which are good potential for such partnership. We feel pretty confident to have this Emerging Market strategic alliance come to fruition.